Post Profile






Novartis closes Swiss, Chinese centers in research revamp

ZURICH (Reuters) - Novartis said on Wednesday it was shuttering research centers in Switzerland and China, part of the Swiss drug maker's bid to trim some costly locations and centralize control over its drug discovery programs.
read more

share

Related Posts


Novartis cutting 2,500 jobs globally-paper | Reuters

Medical / Pharmaceutical : PharmaGossip

(Reuters) - Swiss drugmaker Novartis is in the process of cutting 2,500 jobs at sites across the world in a bid to control costs, daily Tages Anzeiger reported on Saturday. Like many pharmaceutical companies, Novartis is starting to...

Drug maker draws fire over price hike for decades-old lead poisoning treament

Business & Finance : Mashable: Business

A drug used to treat lead poisoning is causing a toxic reaction among hospitals and poison control centers after Valeant Pharmaceuticals jacked up the price more than 2,700 percent in a single year. At issue is a decades-old, intrav...

Rise In Swiss Forex Reserves Suggests SNB Still Curbing Franc

Business & Finance : Business Insider: Clusterstock

ZURICH (Reuters) - Switzerland's foreign exchange reserves hit a record high in January, data showed, suggesting its central bank is still actively curbing the franc with interventions one researcher estimated at close to 2 billion ...

Novartis to disband cell & gene therapy unit, 120 jobs to go

Health : Reuters: Health

ZURICH (Reuters) - Novartis is folding activities of its Cell and Gene Therapy unit into other business and research locations, eliminating 120 positions, the Swiss drugmaker said on Wednesday.

Novartis bid to sell new biosimilar crimped by U.S. court battles

Health : Reuters: Health

ZURICH (Reuters) - Novartis has won U.S. approval for a copy of Amgen's blockbuster arthritis drug Enbrel, but the Swiss drugmaker's bid to muscle in on the medicine's $4.7 billion in annual U.S. revenue remains blocked by court bat...

Comments


Copyright © 2016 Regator, LLC